EGFR ex20ins exhibit significant heterogeneity, with extensive research and theories confirming that NSCLC with EGFR ex20ins mutations presents primary resistance to approved EGFR-TKIs. This evidence concerns the gene EGFR and non-small cell lung carcinoma.